- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 389056, 7 pages
On Benzofuroindole Analogues as Smooth Muscle Relaxants
Uimyung Research Institute for Neuroscience and Department of Pharmacology, Sahmyook University, 26-21 Kongkreung-dong, Nowon-gu, 139-742 Seoul, Republic of Korea
Received 3 May 2011; Accepted 14 July 2011
Academic Editor: J.-P. Jin
Copyright © 2011 Ike dela Peña and Jae Hoon Cheong. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. J. Morrison and J. M. Rennie, “Clinical, scientific and ethical aspects of fetal and neonatal care at extremely preterm periods of gestation,” British Journal of Obstetrics and Gynaecology, vol. 104, no. 12, pp. 1341–1350, 1997.
- H. Karaki, H. Ozaki, M. Hori et al., “Calcium movements, distribution, and functions in smooth muscle,” Pharmacological Reviews, vol. 49, no. 2, pp. 157–230, 1997.
- A. Vander, J. Sherman, and D. Laciano, Human Physiology: The Mechanism of Body Function, McGraw-Hill, Boston, Mass, USA, 8th edition, 2001.
- A. J. Pappano, “Cholinoceptor-activating and cholinesterase-inhibiting drugs,” in Basic and Clinical Pharmacology, B. G. Katzung, Ed., pp. 93–107, McGraw-Hill, Singapore, 2007.
- T. Godfraind, R. Miller, and M. Wibo, “Calcium antagonism and calcium entry blockade,” Pharmacological Reviews, vol. 38, no. 4, pp. 321–416, 1986.
- T. Uchiyama and R. Chess-Williams, “Muscarinic receptor subtypes of the bladder and gastrointestinal tract,” Journal of Smooth Muscle Research, vol. 40, no. 6, pp. 237–247, 2004.
- E. P. Frazier, S. L. Peters, A. S. Braverman, M. R. Ruggieri, and M. C. Michel, “Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoreceptors,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 377, pp. 449–462, 2007.
- H. H. Zingg and S. A. Laporte, “The oxytocin receptor,” Trends in Endocrinology and Metabolism, vol. 14, no. 5, pp. 222–227, 2003.
- L. Myatt and S. J. Lye, “Expression, localization and function of prostaglandin receptors in myometrium,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 70, no. 2, pp. 137–148, 2004.
- A. Shmygol, J. Gullam, A. Blanks, and S. Thornton, “Multiple mechanisms involved in oxytocin-induced modulation of myometrial contractility,” Acta Pharmacologica Sinica, vol. 27, no. 7, pp. 827–832, 2006.
- A. Carl, H. K. Lee, and K. M. Sanders, “Regulation of ion channels in smooth muscles by calcium,” American Journal of Physiology, vol. 271, no. 1, pp. C9–C34, 1996.
- P. R. Conlin and G. H. Williams, “Use of calcium channel blockers in hypertension,” Advances in Internal Medicine, vol. 43, pp. 533–562, 1998.
- B. Cantabrana, J. R. Perez Vallina, L. Menéndez, and A. Hidalgo, “Spasmolytic and calmodulin inhibitory effect of non-steroidal anti-inflammatory drugs in vitro,” Life Sciences, vol. 57, no. 14, pp. 1333–1341, 1995.
- T. M. Argentieri and J. A. Butera, “An overview of potassium channel activators for the treatment of overactive bladder: a survey of new structures 2000–2005,” Expert Opinion on Therapeutic Patents, vol. 16, no. 5, pp. 573–585, 2006.
- K. Gyetvai, M. E. Hannah, E. D. Hodnett, and A. Ohlsson, “Tocolytics for preterm labor: a systematic review,” Obstetrics and Gynecology, vol. 94, no. 5, pp. 869–877, 1999.
- N. D. Berkman, J. M. Thorp Jr., K. N. Lohr et al., “Tocolytic, treatment for the management of preterm labor: a review of the evidence,” American Journal of Obstetrics and Gynecology, vol. 188, no. 6, pp. 1648–1659, 2003.
- J. H. Sheldon, N. W. Norton, and T. M. Argentieri, “Inhibition of guinea pig detrusor contraction by NS-1619 is associated with activation of and inhibition of calcium currents,” Journal of Pharmacology and Experimental Therapeutics, vol. 283, no. 3, pp. 1193–1200, 1997.
- C. D. Foster, M. J. Speakman, K. Fujii, and A. F. Brading, “The effects of cromakalim on the detrusor muscle of human and pig urinary bladder,” British Journal of Urology, vol. 63, no. 3, pp. 284–294, 1989.
- G. Edwards, M. Henshaw, M. Miller, and A. H. Weston, “Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro,” British Journal of Pharmacology, vol. 102, no. 3, pp. 679–686, 1991.
- R. Chess-Williams, S. W. Martin, C. Korstanje, and C. R. Chapple, “In vitro investigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues,” British Journal of Urology International, vol. 83, no. 9, pp. 1050–1054, 1999.
- M. E. Brune, T. A. Fey, J. D. Brioni et al., “(-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. In vivo characterization,” Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 1, pp. 387–394, 2002.
- A. C. Fabiyi, M. Gopalakrishnan, J. J. Lynch, J. D. Brioni, M. J. Coghlan, and M. E. Brune, “In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats,” British Journal of Urology International, vol. 91, no. 3, pp. 284–290, 2003.
- K. Komersova, J. W. Rogerson, E. L. Conway et al., “The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions,” British Journal of Clinical Pharmacology, vol. 39, no. 2, pp. 207–209, 1995.
- J. A. Butera, S. A. Antane, B. Hirth et al., “Synthesis and potassium channel opening activity of substituted 10H-benzo[4,5]furo[3,2-b]indole- and 50-dihydro-indeno[1,2-b]indole-1-carboxylic acids,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 16, pp. 2093–2097, 2001.
- A. E. Gormemis, T. S. Ha, I. Im et al., “Benzofuroindole analogues as potent channel openers,” ChemBioChem, vol. 6, no. 10, pp. 1745–1748, 2005.
- I. C. Dela Peña, S. Y. Yoon, S. M. Kim et al., “Bladder-relaxant properties of the novel benzofuroindole analogue LDD175,” Pharmacology, vol. 83, no. 6, pp. 367–378, 2009.
- M. L. Garcia, D. M. Shen, and G. J. Kaczorowski, “High-conductance calcium-activated potassium channels: validated targets for smooth muscle relaxants?” Expert Opinion on Therapeutic Patents, vol. 17, no. 7, pp. 831–842, 2007.
- S. H. Tal, H. H. Lim, E. L. Ga, Y. C. Kim, and C. S. Park, “Electrophysiological characterization of benzofuroindole-induced potentiation of large-conductance Ca2+-activated K+ channels,” Molecular Pharmacology, vol. 69, no. 3, pp. 1007–1014, 2006.
- G. J. Kaczorowski, H. G. Knaus, R. J. Leonard, O. B. McManus, and M. L. Garcia, “High-conductance calcium-activated potassium channels: structure, pharmacology, and function,” Journal of Bioenergetics and Biomembranes, vol. 28, no. 3, pp. 255–267, 1996.
- S. Ghatta, D. Nimmagadda, X. Xu, and S. T. O'Rourke, “Large-conductance, calcium-activated potassium channels: structural and functional implications,” Pharmacology and Therapeutics, vol. 110, no. 1, pp. 103–116, 2006.
- M. A. Valverde, P. Rojas, J. Amigo et al., “Acute activation of Maxi-K channels (hSlo) by estradiol binding to the β subunit,” Science, vol. 285, no. 5435, pp. 1929–1931, 1999.
- M. Wallner, P. Meera, and L. Toro, “Molecular basis of fast inactivation in voltage and Ca2+-activated K+ channels: a transmembrane β-subunit homolog,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 4137–4142, 1999.
- X. M. Xia, J. P. Ding, and C. J. Lingle, “Molecular basis for the inactivation of Ca2+- and voltage-dependent BK channels in adrenal chromaffin cells and rat insulinoma tumor cells,” Journal of Neuroscience, vol. 19, no. 13, pp. 5255–5264, 1999.
- X. Qian, C. M. Nimigean, X. Niu, B. L. Moss, and K. L. Magleby, “Slo1 tail domains, but not the Ca2+ bowl, are required for the β1 subunit to increase the apparent Ca2+ sensitivity of BK channels,” Journal of General Physiology, vol. 120, no. 6, pp. 829–843, 2002.
- C. Vergara, R. Latorre, N. V. Marrion, and J. P. Adelman, “Calcium-activated potassium channels,” Current Opinion in Neurobiology, vol. 8, no. 3, pp. 321–329, 1998.
- M. J. Coghlan, W. A. Carroll, and M. Gopalakrishnan, “Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress,” Journal of Medicinal Chemistry, vol. 44, no. 11, pp. 1627–1653, 2001.
- G. M. Dick, A. C. Hunter, and K. M. Sanders, “Ethylbromide tamoxifen, a membrane-impermeant antiestrogen, activates smooth muscle calcium-activated large-conductance potassium channels from the extracellular side,” Molecular Pharmacology, vol. 61, no. 5, pp. 1105–1113, 2002.
- Y. Imaizumi, K. Sakamoto, A. Yamada et al., “Molecular basis of pimarane compounds as novel activators of large-conductance Ca2+-activated K+ channel α-subunit,” Molecular Pharmacology, vol. 62, no. 4, pp. 836–846, 2002.
- K. M. Giangiacomo, A. Kamassah, G. Harris, and O. B. Mcmanus, “Mechanism of maxi-K channel activation by dehydrosoyasaponin-I,” Journal of General Physiology, vol. 112, no. 4, pp. 485–501, 1998.
- G. J. Kaczorowski and M. L. Garcia, “Pharmacology of voltage-gated and calcium-activated potassium channels,” Current Opinion in Chemical Biology, vol. 3, no. 4, pp. 448–458, 1999.
- A. Nardi and S. P. Olesen, “ channel modulators: a comprehensive overview,” Current Medicinal Chemistry, vol. 15, no. 11, pp. 1126–1146, 2008.
- G. McMurray, J. H. Casey, and A. M. Naylor, “Animal models in urological disease and sexual dysfunction,” British Journal of Pharmacology, vol. 147, no. 2, pp. S62–S79, 2006.
- I. C. Dela Peña, S. Y. Yoon, S. M. Kim et al., “Inhibition of intestinal motility by the putative channel opener LDD175,” Archives of Pharmacal Research, vol. 32, no. 3, pp. 413–420, 2009.
- H. S. Ahn, I. dela Peña, J. H. Ryu, Y. C. Kim, and J. H. Cheong, “4-chloro-7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid (TBIC), a putative channel opener with uterine-relaxant activities,” Pharmacology, vol. 1, no. 87(5-6), pp. 331–340, 2011.
- R. N. Khan, B. Matharoo-Ball, S. Arulkumaran, and M. L. J. Ashford, “Potassium channels in the human myometrium,” Experimental Physiology, vol. 86, no. 2, pp. 255–264, 2001.
- B. Chanrachakul, B. Matharoo-Ball, A. Turner et al., “Immunolocalization and protein expression of the α subunit of the large-conductance calcium-activated potassium channel in human myometrium,” Reproduction, vol. 126, no. 1, pp. 43–48, 2003.
- R. Schubert and M. T. Nelson, “Protein kinases: tuners of the channel in smooth muscle,” Trends in Pharmacological Sciences, vol. 22, no. 10, pp. 505–512, 2001.
- J. Malysz, S. A. Buckner, A. V. Daza, I. Milicic, A. Perez-Medrano, and M. Gopalakrishnan, “Functional characterization of large conductance calcium-activated K+ channel openers in bladder and vascular smooth muscle,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 369, no. 5, pp. 481–489, 2004.
- H. Kobayashi, S. Adachi-Akahane, and T. Nagao, “Involvement of channels in the relaxation of detrusor muscle via β-adrenoceptors,” European Journal of Pharmacology, vol. 404, no. 1-2, pp. 231–238, 2000.